These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 12625216)

  • 1. Biological response modifiers in the management of rheumatoid arthritis.
    Louie SG; Park B; Yoon H
    Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular differences in anticytokine therapies.
    Calabrese LH
    Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
    Fleischmann RM; Iqbal I; Stern RL
    Expert Opin Drug Saf; 2004 Sep; 3(5):391-403. PubMed ID: 15335295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 8. The mode of action of cytokine inhibitors.
    Arend WP
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of new biologicals in the treatment of rheumatoid arthritis.
    Weaver AL
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii17-iii23. PubMed ID: 15150428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cytokine therapy for rheumatoid arthritis.
    Maini RN; Taylor PC
    Annu Rev Med; 2000; 51():207-29. PubMed ID: 10774461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
    Shanahan JC; St Clair W
    Clin Immunol; 2002 Jun; 103(3 Pt 1):231-42. PubMed ID: 12173297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].
    Botsios C; Ostuni P; Sfriso P; Furlan A; Fiocco U; Sgarabotto D; Todesco S
    Reumatismo; 2003; 55(4):224-35. PubMed ID: 14872221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].
    Sautner J; Leeb BF
    Wien Med Wochenschr; 2003; 153(13-14):304-8. PubMed ID: 12924105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of rheumatoid arthritis: old versus new therapies.
    Saravanan V; Hamilton J
    Expert Opin Pharmacother; 2002 Jul; 3(7):845-56. PubMed ID: 12083985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-17 gene expression in patients with rheumatoid arthritis.
    Kohno M; Tsutsumi A; Matsui H; Sugihara M; Suzuki T; Mamura M; Goto D; Matsumoto I; Ito S; Suguro T; Sumida T
    Mod Rheumatol; 2008; 18(1):15-22. PubMed ID: 18092129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.